55/100
Dementia constitutes a worldwide concern. 4 key findings →
Participants: 497,401 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Increasing neighborhood disadvantage was associated with increased risk of EHR-documented dementia diagnosis or dementia-related death (most vs. least disadvantaged ADI quintile HR = 1.76, 95% confidence interval = 1.69-1.84) after adjusting for age and sex. 4 key findings →
Participants: 253,421 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In this analytic cohort of 4130 participants, 486 (11.8%) experienced at least one hospitalization with delirium. 5 key findings →
Design: prospective cohort Participants: 4,130 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Participants with more FTUs were found to have a slower biological ageing process. 5 key findings →
Participants: 22,900 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of 9,361 SPRINT participants (mean age 67.1 ± 9.5 years, 36.7% female, 58.7% non-Hispanic White), 710 and 1,289 were new users of an ARB or ACEI. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
55/100
There was a significantly higher risk of developing a dementia diagnosis in Hispanic/Latino and NHB participants than NHW participants and comparably increased dementia hazard ratios in the Hispanic/Latino, NHB, and NHW APOE4 carriers than non-carriers (hazard ratio [HR] [95% confidence interval {CI}] 1.54 [1.25-1.91], 1.25 [1.00-1.57], and 1.55 [1.40-1.72]). 5 key findings →
Design: longitudinal study Participants: 9,784 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
55/100
Among 24 762 people with HIV and 494 963 people without HIV (86.9% men, 45.5% White, 23.1% Black, 20.3% Hispanic), incident dementia diagnoses declined from 2000 to 2023 in both people with and without HIV (-7.68 and -2.70% per period, respectively). 5 key findings →
Design: retrospective cohort Participants: 762 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
After 3.5 years of follow up, 19 new cases of dementia were identified among 229 surviving participants. 5 key findings →
Design: cohort study Participants: 341 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 2,218 participants, 237 (11%) developed dementia in the period 1992/3 to 2015/6. 5 key findings →
Design: cohort study Participants: 2,218 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The incidence of dementia was 0.68 (95% CI 0.64-0.72) cases per 100 person-years in pSS, and it was 0.58 (0.56-0.60) in the controls. 5 key findings →
Design: cohort study Participants: 20,160 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
55/100
Between Sept 1, 2017, and Feb 28, 2019, 19 403 individuals were invited to participate and 9745 participants (1525 with dementia, 8220 without dementia) were included. 4445 (45·6%) of 9745 participants were male and 5300 (54·4%) were female. 5 key findings →
Design: cohort study Participants: 403 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 8994 and 14 720 participants were involved in the change-to-change analyses and change-to-dementia analyses, respectively. 5 key findings →
Design: longitudinal study Participants: 720 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
During an average follow-up of 3.63 years, we observed a total of 1 493 individuals developing dementia among 4 341 depressed and 43 214 matched non-depressed individuals (62.4% female; mean [SD] age at baseline 64.4 [11.1] years). 5 key findings →
Design: longitudinal study Participants: 493 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
55/100
The data of 508,107 individuals were analyzed (mean [standard deviation] age, 67.6 [10.7] years; 66.8% women and 33.2% men), and 39,318 developed Alzheimer's disease (22,572 controls and 16,746 using aspirin). 5 key findings →
Design: cohort study Participants: 508,107 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 1,528,885 adults with type 2 diabetes (mean age, 58 years; 49.2% women), GLP-1 receptor agonists plus metformin were associated with lower incidence of vascular dementia (HR, 0.46; 95% CI, 0.37-0.57), mild cognitive disorder (HR, 0.79; 95% CI, 0.66-0.95), and Alzheimer disease (HR, 0.46; 95% CI, 0.31-0.70). 5 key findings →
Design: cohort study Participants: 1,528,885 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
55/100
Chronological age is an imperfect estimate of molecular aging. 5 key findings →
Participants: 4,018 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
There were 656 deaths, 1585 incidents of CVD and 165 dementia diagnoses during 17.2 years of follow-up. 5 key findings →
Design: longitudinal study Participants: 9,584 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cognitive decline and dementia have a deep impact on the health and quality of life of older subjects and their caregivers. 3 key findings →
Design: longitudinal study Evidence: high
Full summary, score breakdown and related studies → Original source
This study found no evidence that major lifestyle factors, aside from smoking, or sleep duration influence the risk of dementia. 4 key findings →
Participants: 3,755 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Compared with non-dementia patients, hospitalised dementia patients have higher rates of potentially preventable complications that might be responsive to nursing interventions. 4 key findings →
Design: retrospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source
55/100
Uncontrolled diabetes increases the risk of Alzheimer's disease and VaD. 4 key findings →
Participants: 1,248 Evidence: moderate
Full summary, score breakdown and related studies → Original source
54/100
CKD is independently related to the risk of all-cause dementia in patients with vascular risk factors. 5 key findings →
Participants: 600 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
54/100
Caffeine stimulates central nervous system on a short term. 3 key findings →
Participants: 1,409 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Vascular disease in the brain is prevalent among incident dementia cases. 1 key finding →
Participants: 3,375 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Studies of autosomal dominant Alzheimer disease (AD) have shown structural and cognitive changes in mutation carriers decades prior to clinical disease. 1 key finding →
Participants: 717 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
10 of the 1,141 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Healthy lifestyle and life expectancy with and without Alzheimer's dementia: population based cohort study
- Midlife and late-life obesity and the risk of dementia: cardiovascular health study
- Associations of early-onset coronary heart disease and genetic susceptibility with incident dementia and white matter hyperintensity: A prospective cohort study
- Using real world data to visualize longitudinal modifiable dementia risk factors in the community through an online interactive map
- Association of dietary diversity, genetic susceptibility, and the risk of incident dementia: A prospective cohort study
- Vascular risk factors, cognitive decline, and dementia
- Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis
- Feelings of loneliness, but not social isolation, predict dementia onset: results from the Amsterdam Study of the Elderly (AMSTEL)
- Hypoglycemia as a risk factor for dementia in diabetes: A systematic review
- Glucagon-like peptide-1 receptor agonist initiation and risk of clinically recorded Alzheimer's disease-type dementia in older adults with type 2 diabetes: a target trial emulation using causal machine learning
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →